Immunophenotypic profile of adult acute lymphoblastic leukaemia in Iraq, a one year experience

Israa M. Al-Bayaa¹, Zakaa N. Al-Nidawy², Yasaamin A. Al-Amiri², Ikball M. Hajem²

¹ Department of Pathology/ College of medicine /Kerbala University.
² Hematology department Baghdad teaching laboratories/medical city/Baghdad

Abstract:

Background: Acute lymphoblastic leukaemia accounts for approximately 14% of leukaemia cases in the adults with B lineage subtype being more common than T lineage subtype. immunophenotyping using the multicolour flow cytometry is an essential tool for diagnosis, classification as well as treatment guidance and prognosis.

Objectives: This study aims to provide an overview of the immunophenotypic profile of adult ALL cases in Iraq, it’s possible link with other characters and also study the frequency of expression of aberrant myeloid antigens in them.

Patients and methods: this is a descriptive study included 64 adult patients diagnosed as ALL in haematology unit at Baghdad teaching hospital for the period between May 2014 till May 2015, immunophenotyping was carried out at the flow cytometry laboratory in the nursing home hospital using 6 coloured (BD-FACS-Canto II System from Becton Dickenson).

Results: of the study population 63.7% of the cases were B-ALL and 27.5% were T-ALL, there was no significant difference in respect to age and gender between them. Of the CD markers used both CD10 and CD34 were significantly associated with B-ALL compared to T-ALL (p values 0.002 and 0.003 respectively). aberrant myeloid Ag expression was seen in 43.18% of B-ALL cases and in 52.6% of T-ALL cases with no significant difference however aberrant myeloid Ag expression was significantly associated with CD34 expression with a p value of 00.018.

Conclusion: Immunophenotyping retains a crucial place in the work up for patients with acute lymphoblastic leukaemia. CD34 was significantly associated with B lineage ALL and with aberrant myeloid Ag expression, larger study with clinical evaluation and cytogenetic study is recommended to evaluate the impact of those findings over prognosis.

Key words: immunophenotyping, B-ALL, T-ALL, multichannel flow cytometry, aberrant myeloid Ag expression.

Introduction:

Acute lymphoblastic leukaemia is a common neoplasm of haemopoietic precursors that occur with a higher frequency in children than in adults. In adults ALL accounts approximately for 14% of leukaemia cases with an incidence estimated to be less than 1 % (1). In the early classification schemes the classification was based mainly on cytomorphology supplemented by immunohistochemistry (FAB classification). The recent WHO classification emphasizes the use of immunophenotyping for accurate categorization of ALL cases and abandons the use of FAB classification as it has no prognostic or therapeutic implications. In the

WHO classification precursor lymphoid neoplasms are classified into precursor B lymphoblastic leukaemia/lymphoma and to precursor T lymphoblastic leukaemia/lymphoma (2). Immunophenotyping by means of multi-channel flow cytometry (MFC) has become the standard procedure for ALL diagnosis and subclassification, and was also developed as useful tool for the detection and monitoring of minimal residual disease (3). Flow cytometry can identify several cellular properties, including size, cytoplasmic and nuclear complexity. It can provide correlated data that links different population profiles all based on single cell analysis. (4) In Iraq immunophenotyping has only been recently introduced to the panel of investigations for ALL. The aim of this study is to provide an overview of the immunophenotypic profile of adult ALL cases in Iraq and also study the frequency of expression of aberrant myeloid antigens in them.

Corresponding address:
Israa M. Al-Bayaa
Department of Pathology/ College of medicine /Kerbala University.
Email: khaled59@yahoo.com
Patients and methods:

A total of 64 adult (age more than 18 years) untreated newly diagnosed ALL patients admitted to the haematology unit at Baghdad teaching hospital for the period between May 2014 till May 2015 were included in this study, informed consent was taken from the study population. ALL Diagnosis was based on morphology and immunophenotyping. Immunophenotyping was carried out at the flow cytometry laboratory in the nursing home hospital using 6 coloured (BD-FACS-Canto II System from Becton Dickenson). Either peripheral blood or bone marrow samples were used according to the availability and blast percentage. Blood or the bone marrow samples were collected in EDTA tubes and processed within 24 hours of collection a panel of fluorochrome-conjugated monoclonal antibodies were used, all the antibodies were obtained from Becton Dickenson (USA). Fluorochromes used were fluoroscein isothiocyanate (FITC), phycoerythrin (PE) or perdinin chlorophyll protein (PerCP), and were directed to the following antigens CD1a, CD2, cytoplasmic (c) CD3, CD4, CD5, CD7 and CD8 ,CD10, CD19, CD20 and cCD79a ,CD13, CD33, CD117, CD11b, cytoplasmic myeloperoxidase (MPO), CD14, CD15 CD64 CD34, CD38 human leukocyte antigen-DR (HLA-DR), CD56 and cytoplasmic TdT.

Data acquisition and sample analysis was performed in a BD FACS CantoII (6- color, Becton Dickinson, USA), using FACSCANTO Diva (Becton Dickinson), after calibration with the Calibrate bead kit (Becton Dickinson). The blast gating strategy included using dot plots of CD45 expression versus intracellular complexity (side scatter angle, SSC). A total of 10,000 events were acquired in the target gate. Antigen was considered as positive if 20% or more of the blast cells reacted with a particular antibody. Statistical analysis was done using SPSS 20, Chi square test was used for categorical variables, and student t test was used for continuous variables, values less than 0.005 were considered as significant.

Results:

Patient’s characteristics: in this descriptive study 64 adult patients diagnosed with ALL during the study period were included in the study, 40 males with a mean age of 30.46±13.18 and 24 females with a mean age of 35.21±15.24, there was no statistically significant difference for the age between males and females. The majority of the patients were less than 25 years old (16 of B-ALL and 7 of T-ALL) with only one case of B-ALL was older than 65 years, all the results are summarized in figure 1.

Immunophenotypic characteristics of ALL subtypes:

According to immunophenotyping results, 44 of the cases were B lineage -ALL, 19 cases were T lineage -ALL and one case was diagnosed as Blastic plasmacytoid dendritic cell neoplasia. From the B lineage ALL 39 of the cases showed CD10 expression and considered as common ALL and only 5 cases were CD10 negative. The expression of the various CD markers in ALL subtypes is summarized in table 1. CD10 and CD34 expressions were associated with B-ALL rather than T-ALL as shown by Chi square test with a p value of 0.002 and 0.003 respectively. On the other hand HLA-DR expression was seen in all the B Linage cases while only 6 cases of T linage ALL were positive for this marker with a highly significant difference (p value less than 0.001). As expected markers that are specifically associated with B-ALL (19,20,79a) or with T-ALL (CD2,CD3,CD4,CD5,CD7,CD8) were highly significantly different between the two types of leukaemia.

Figure (1): age distribution of the study population.
CD markers positive

<table>
<thead>
<tr>
<th></th>
<th>(B- ALL (44)) (63.7%)</th>
<th>(T- ALL (19)) (27.5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>(%) Percentage</td>
<td>Number</td>
</tr>
<tr>
<td>CD34</td>
<td>36</td>
<td>81.8%</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>44</td>
<td>100%</td>
</tr>
<tr>
<td>CD38</td>
<td>29</td>
<td>65.9%</td>
</tr>
<tr>
<td>CD1a</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD2</td>
<td>1</td>
<td>2.27%</td>
</tr>
<tr>
<td>CD3</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD4</td>
<td>1</td>
<td>2.27%</td>
</tr>
<tr>
<td>CD5</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD7</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD8</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD10</td>
<td>39</td>
<td>88.6%</td>
</tr>
<tr>
<td>CD19</td>
<td>42</td>
<td>95.4%</td>
</tr>
<tr>
<td>CD20</td>
<td>28</td>
<td>63.6%</td>
</tr>
<tr>
<td>CD79a</td>
<td>37</td>
<td>84.09%</td>
</tr>
<tr>
<td>CD11b</td>
<td>3</td>
<td>1.3%</td>
</tr>
<tr>
<td>CD33</td>
<td>11</td>
<td>25%</td>
</tr>
<tr>
<td>CD13</td>
<td>12</td>
<td>27.2%</td>
</tr>
<tr>
<td>CD14</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD15</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD16</td>
<td>3</td>
<td>6.8%</td>
</tr>
<tr>
<td>CD64</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD117</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>cTdT</td>
<td>41</td>
<td>93.1%</td>
</tr>
<tr>
<td>cMPO</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>CD56</td>
<td>2</td>
<td>4.5%</td>
</tr>
</tbody>
</table>

Table (1): the expression of various CD markers in ALL subtypes.

Of the common B lineage CD markers CD19 was the most common present in about 95.4% of the B-ALL cases followed by cTdT (93.1%), the frequency of expression of B lineage CD markers in B-ALL is illustrated in figure 2.
For T lineage ALL the commonest CD marker was CD7 that was expressed in 100% of the cases followed by cytoplasmic CD3 all these findings are summerized in figure (3)

Aberrant myeloid Ag expression in ALL subtypes:
Out of the 64 cases included in the study aberrant expression of CD13, CD33,CD16 and CD 11b was seen in 19 cases of B-ALL (43.18%) and in 10 cases of T-ALL (52.6%) , double expression of CD13 and CD33 was seen in 6 cases of B-ALL and only in one case of T-ALL . No significant association was found between ALL subtypes and aberrant Ag expression with a p value of 0.357, all the data are summarized in table 2

Table (2): the frequency of aberrant myeloid Ag expression in different ALL subtypes

<table>
<thead>
<tr>
<th>Aberrant Ag expression</th>
<th>B-ALL (44)</th>
<th>T-ALL(19)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Percentage (%)</td>
</tr>
<tr>
<td>CD13</td>
<td>12</td>
<td>27.2%</td>
</tr>
<tr>
<td>CD33</td>
<td>11</td>
<td>25%</td>
</tr>
<tr>
<td>CD16</td>
<td>3</td>
<td>6.8%</td>
</tr>
<tr>
<td>CD11b</td>
<td>3</td>
<td>6.8%</td>
</tr>
<tr>
<td>CD13 and CD33</td>
<td>6</td>
<td>13.6%</td>
</tr>
</tbody>
</table>

However when compared with the other CD markers Aberrant myeloid Ag expression was significantly associated with CD34 expression with a p value of 0.018.

Two cases of B-ALL showed aberrancy for T lineage marker, one was expressing CD4 and the other CD2. While none of the T-ALL cases showed B-lineage markers expression.

Only one case was diagnosed as Blastic plasmacytoid dendritic cell neoplasia that showed a unique combination of

Discussion:

Immunophenotyping is an essential part of assessment of haematological malignancies and the multicolour flow cytometry can provide useful tool for accurate categorization of these neoplasms providing valuable information regarding the type, subtype as well as treatment guidance and prognosis (5).

In Iraq multicolour flow cytometry has been recently added to the panel of investigations required for assessment of acute leukaemia and this study aims to provide an overall view of the immunophenotypic characteristics of adult ALL cases through the study period that lasted for one year.

In the current study ;The frequency of B-ALL was found to be higher than that of T-ALL (63.7% versus 27.5%) which is quite similar to the frequency demonstrated in most of the other studies(6). The mean age for B-ALL cases was 32.81±14.43 while for T-ALL it was 31.63±13.87 and the difference was not statistically significant. Like most of the other studies the majority of the patients were less than 25 years old for both B-ALL and T-ALL with only one case with B-ALL was older than 65 years. Indeed ALL is a common malignancy in paediatric and adolescence age group (7).

40 of the patients were males and 24 were females with an M:F ratio of 1.6:1 which is slightly higher than the frequency demonstrated in other studies(8,9), this slight male predominance could be due to the sample size or lack of compliance among female patients or possibly due to different population studied .

In the study population B-ALL was seen in about 63.7% of the patients as compared to T-ALL (27.5%) which is a finding quite comparable to other studies like the study of Tong H in China that showed the prevalence of T-ALL among adult patients to be 21.8% (10) and the study of Lahjouji A in Morocco where 30.1 % of adult ALL cases were T-ALL (11). Of the B lineage ALL cases CD10 expression was demonstrated in about 88.6% of the cases that were accordingly categorized as common B-ALL and 11.4% of the cases were negative to that Ag . Surface membrane Immunoglobulin was not included in the Ag panel for patients with leukaemia therefore it was not possible to identify the mature B-ALL subtype. Furthermore, CD10 and CD34 expressions were both significantly higher in B-ALL cases than in T-ALL and many studies have issued the influence of it's expression or it's co-expression with CD34 over treatment outcome and overall survival (12,13,14) .

Aberrant myeloid Ag expression was seen in 43.18% of B-ALL cases and in 52.6% of T-ALL cases. The expression of myeloid antigens in acute lymphoblastic leukaemia is quite common with a wide range of incidence as has been reported by many other studies like the study by Adam C (15) where aberrant myeloid Ag was demonstrated in 86.5% of the cases of these antigens CD13 is the most common followed by CD33. In another study myeloid Ag expression was demonstrated in about one third of the cases (16) , not only the incidence of myeloid Ag expression but also it’s impact over prognosis has been a subject of debate for many researches . In the current study a significant association was demonstrated between CD34 expression and aberrant myeloid Ag expression, a finding that has been shown in a previous study by Sharma R (17), the value of this association needs to be further investigated as CD34 expression has been linked with prognosis in many studies (18,19)and whether it’s association with myeloid Ag expression is a consistent finding needs a
larger study with clinical evaluation and follow up in order to
determine its impact over treatment response and prognosis.

Conclusions:

Immunophenotyping retains a crucial place in the work up
for patients with acute lymphoblastic leukemia. In the current study which examined ALL in adult patients; B-ALL was
more frequent with significant association with CD34 expres-
sion than T-ALL. Myeloid Ag was expressed in both of them
however myeloid Ag expression has been shown to be signifi-
cantly associated with CD34 expression.

A larger study including larger number of patients with
clinical evaluation and if possible cytogenetic study is recom-
pended to evaluate the value of this association over treat-
ment outcome and prognosis.

References:

1. Estey EH, Faderl S, Kantarjian H (eds).(2008). Acute leukemias,
1st edn. Texas: Springer.
2. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S” Pileri S.A.,
Stein H” Thiele J , Vardiman J. w. (2008).(Eds.):WHO Classification
of Tumours of Haematopoietic and Lymphoid Tissues, IARC: Lyon.
Braylan R, et al. (1999) Clinically useful information provided by
the flow cytometric immunophenotyping of hematological malig-
nancies: current status and future directions. Clinical chemistry
45:1708-1717
WD, et al. (1999) Impact of immunophenotyping on management
of acute leukemias. Haematologica 84:1024-1034
A et al. (1994) Immunophenotype of adult acute lymphoblastic
leukemia, clinical parameters, and outcome: an analysis of a pro-
spective trial including 562 tested patients (LALA87). French
Group on Therapy for Adult Acute Lymphoblastic Leukemia.
Blood 84:1603-1612
Blackwell, Chichester, West Sussex, UK ; Hoboken, NJ
al.(2011) [Probe of classification of adult acute lymphoblastic
leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue
zazhi 32:439-444
P et al. (2013) Clinico-biological features of 5202 patients with
acute lymphoblastic leukemia enrolled in the Italian AIEOP and
GIMEMA protocols and stratified in age cohorts. Haematologica
98:1702-1710
typic, Cytogetnetic and Clinical Features in Chinese Adult Acute
Lymphoblastic Leukaemia (ALL) Patients. Annals of the Acad-
emy of Medicine, Singapore 43:152-159
M et al. (2009) Characterization of acute lymphoblastic leukemia
subtypes in moroccan children. International journal of pediatrics
2009:674801
12. Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E,
Lippi A et al. (1998) Clinical relevance of CD10 expression in
childhood ALL. The Italian Association for Pediatric Hematol-
ogy and Oncology (AIEOP). Haematologica 83:967-973
13. Dakka N, Bellaoui H, Bouzid N, Khatbib M, Bakri Y, Benjouad
A (2009) CD10 AND CD34 expression in childhood acute lym-
phoblastic leukemia in Morocco: clinical relevance and outcome.
Pediatric hematology and oncology 26:216-231
and long-term prognostic value of CD34 in childhood and adult
acute lymphoblastic leukemia. Leukemia & lymphoma 20:137-
142
15. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW (2009)
Characterization of immunophenotypic aberrancies in 200 cases
of B acute lymphoblastic leukemia. American journal of clinical
pathology 132:940-949
16. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR,
Powell BL et al.(1999) Value of immunophenotype in intensively
treated adult acute lymphoblastic leukemia: cancer and leukemia
17. Sharma RK, Purohit A, Somasundaram V, Mishra PC, Kotru M,
Ranjai R et al. (2014) Aberrant myeloid antigen co-expression is
correlated with high percentages of CD34-positive cells among
blasts of acute lymphoblastic leukemia patients: an Indian tertiary
care center perspective. Blood research 49:241-245
and long-term prognostic value of CD34 in childhood and adult
acute lymphoblastic leukemia. Leukemia & lymphoma 20:137-
142
CD34 expression is associated with major adverse prognostic fac-
tors in adult acute lymphoblastic leukemia. Leukemia 9:249-253
دراسة حول الصفات المناعية للخلايا في المرضى البالغين المصابين بسرطان الدم اللمفاوي الحاد في العراق، تجربة سنة واحدة

إسراء محمد باقر البياع، زكاء نوري مجيد التداوي، ياسمين علي العامري، اقبال محمد حاجم
1 جامعة كربلاء/ كلية الطب/ فرع الأمارس
2 دائرة مدينة الطب/ المختبرات التعليمية

الخلاصه:

يمثل سرطان الدم اللمفاوي الحاد حوالي 14% من حالات سرطان الدم في البالغين، مع نسبة حدوث تقدر بحوالي أقل من 1%. يعتبر تعيين الخلايا المستند على النمط الظاهري المناعي أحد آليات تشخيص وتصنيف، وكذلك التوجيه العلاجي للأهداف: تهدف الدراسة، هذا إلى تقديم نماذج عامة عن النمط الظاهري المناعي لحالات سرطان الدم اللمفاوي الحاد للبالغين في العراق، و إمكانية ارتباطه مع الخواص الأخرى، وكذلك دراسة وتيرة التعبير عن مستضدات الدم النخاعي الشاذة في حالاتهم. طريقة الدراسة: هذه هي دراسة وصفية شملت تشخيص 64 مريضاً بالاً مصابين بسرطان الدم اللمفاوي الحاد في وحدة أمراض الدم في مستشفى بغداد التعليمي للزماء ما بين مايو 2014 وحتى مايو 2015. تم تقييم التعبير عن النمط الظاهري المناعي للخلايا في مختبر التدفق الخلوي في مستشفى دار التمريض الخاص باستخدام جهاز جرزي (BD-FACS) من بيكون ديكنسون ذو الألوان الستة.

النتائج:

على منحنى القيم من CD10 و CD34، لا يوجد اختلاف كبير بينهما فيما يخص السن والجنس. من بين T-ALL وكانت 27.5% و كانت 21% B-ALL. من الحالات، 32% من T-ALL كانت 0.02 و 3% من B-ALL مقارنة مع CD10 العامل CD34. عدد وأدلة النمط الظاهري المناعي للخلايا النخاعية كانت مرتبطة بشكل كبير مع النمط المناعي CD34. في B-ALL و T-ALL مع نوع CD34، كانت ظهور النمط المناعي الشاذة بالخلايا النخاعية كانت مرتبطة بشكل كبير مع التعبير و الدراسة الوراثية.

الاستنتاج: يحتفظ تعيين الخلايا المستند على النمط الظاهري المناعي بمكانه في تشخيص المرضى المصابين بسرطان الدم اللمفاوي الحاد. تظهر الدراسة الوراثية تأثير تغيير هذه النتائج على أعلام ونتائج هذا المرض.